Connection

WILLEM OVERWIJK to Neoplasms

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Neoplasms.
Connection Strength

0.695
  1. Engineering IL-2 to Give New Life to T Cell Immunotherapy. Annu Rev Med. 2021 01 27; 72:281-311.
    View in: PubMed
    Score: 0.116
  2. The immune system in cancer metastasis: friend or foe? J Immunother Cancer. 2017 10 17; 5(1):79.
    View in: PubMed
    Score: 0.094
  3. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017 Aug; 47:103-109.
    View in: PubMed
    Score: 0.093
  4. Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.
    View in: PubMed
    Score: 0.066
  5. Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy. 2012 Feb; 4(2):141-3.
    View in: PubMed
    Score: 0.063
  6. Breaking tolerance in cancer immunotherapy: time to ACT. Curr Opin Immunol. 2005 Apr; 17(2):187-94.
    View in: PubMed
    Score: 0.039
  7. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.030
  8. The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am. 2000 Feb; 6 Suppl 1:S76-80.
    View in: PubMed
    Score: 0.027
  9. Vaccinating with Stem Cells to Stop Cancer. Trends Mol Med. 2018 06; 24(6):524-526.
    View in: PubMed
    Score: 0.024
  10. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017 Aug; 27(8):1034-1045.
    View in: PubMed
    Score: 0.023
  11. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.021
  12. Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol. 2015 Feb 02; 108:20.1.1-20.1.43.
    View in: PubMed
    Score: 0.019
  13. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014 Jun; 20(6):676-81.
    View in: PubMed
    Score: 0.019
  14. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008 Sep 23; 105(38):14342-6.
    View in: PubMed
    Score: 0.012
  15. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
    View in: PubMed
    Score: 0.012
  16. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006 Aug 15; 12(16):4794-803.
    View in: PubMed
    Score: 0.011
  17. Creating therapeutic cancer vaccines: notes from the battlefield. Trends Immunol. 2001 Jan; 22(1):5-7.
    View in: PubMed
    Score: 0.007
  18. Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst. 1999 Jan 20; 91(2):169-75.
    View in: PubMed
    Score: 0.006
  19. Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
    View in: PubMed
    Score: 0.006
  20. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997 Jun; 12(2):117-23.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.